Hypertrophic Cardiomyopathy: A Contemporary Treatable Disease - International Summit V, Directed by BARRY J. MARON, MDMinneapolis Heart Institute Foundation & Allina HealthFriday, September 27, 2013 at 7:30 AM - Sunday, September 29, 2013 at 12:05 PM (CDT)Minneapolis, MN |
|
Event Details
SUMMIT OVERVIEW
Location
Hyatt Regency, 1300 Nicollet Mall
Minneapolis, MN 55403 USA
Summit Director
Barry J. Maron, MD
Director of the Hypertrophic Cardiomyopathy Center
Minneapolis Heart Institute Foundation
Summit Description
This summit will provide attendees with an opportunity to learn the clinical, morphologic and genetic spectrum of hypertrophic cardiomyopathy (HCM) from a world-renowned faculty. The program will explore the diverse views on the natural history and assessment of risk for sudden death. This CME accredited summit is designed for cardiologists, internists, pediatricians and other health care professionals with an interest in hypertrophic cardiomyopathy.
Target Audience
- Practicing cardiologists, internists, pediatricians and other health care professionals with an interest in HCM.
- Clinicians and basic researchers directly involved with cardiomyopathies.
Learning Objectives
- Identify the clinical, morphologic and genetic spectrum of HCM.
- Explore the diverse views on the natural history and assessment of risk for sudden death.
- Review contemporary management strategies for high-risk and other patient subgroups, including surgical septal myectomy, alcohol septal ablation, pacing, and prevention of sudden death with implantable defibrillators.
- Assess and determine appropriate management of heart failure and arrhythmias, including atrial fibrillation and ventricular tachyarrhythmia.
- Identify mechanisms responsible for adverse clinical events and natural history.
- Learn the role of new diagnostic modalities including magnetic resonance imaging (MRI), positron emission tomography (PET), and advanced echocardiographic techniques.
- Understand the significance and occurrence of left ventricular outflow obstruction.
- Learn to detect and profile HCM in athletic populations and understand the pros and cons of different mass screening strategies for detecting HCM in general populations
- Be appraised of key developments in risk assessment for sudden death, based on detection of myocardial fibrosis with contrast MRI.
Accreditation
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Allina Health and Minneapolis Heart Institute Foundation. Allina Health is accredited by the ACCME to provide continuing medical education for physicians.
Allina Learning & Development, Office of Accreditation at Allina Hospitals & Clinics designates this live activity for a maximum of 19.75 AMA PRA Category 1 Credit(s)TM.
Physicians should only claim credit commensurate with the extent of their participation in the activity.
Disclosure policy
The Center for Learning & Innovation intends to provide balance, independence, objectivity and scientific rigor in all of its sponsored educational activities. All faculty and planning committee members participating in sponsored activities and their spouse/partner are required to disclose to the activity audience any real or apparent conflict(s) of interest related to the content of this summit.
AGENDA
Friday, September 27, 2013
|
Time |
Topic |
| 7:30 |
Registration, continental breakfast, exhibits |
| 8:20 |
Welcome |
|
Genetics, Clinical Diagnosis and Disease Expression |
|
| 8:25 |
Basic principles and introduction to HCM: Definitions, epidemiology, diagnosis, phenotypic expression and pathophysiology |
| 9:00 |
The first quarter century of genomics in HCM: What we have learned about sarcomere HCM and its phenocopies; what does the future hold? |
| 9:35 |
Everything you wanted to know about the realities of genetic testing for HCM: variants of unknown significance and interpretation of the reports |
| 10:10 |
Break |
| 10:40 |
New diagnostic imaging modalities: What CMR has taught us about the HCM disease spectrum - phenotype… myocardium… mitral valve… and beyond echocardiography |
| 11:15 |
Emergence of the genotype positive - phenotype negative HCM subset; Is prevention of the phenotype possible? |
| 11:45 |
Clinical expression & genetic substrate of "HCM" in children |
| 12:15 |
Luncheon Address: How to "discover" a new disease: Reflections on a half-century of investigation |
|
Clinical Course and Prognosis: Heart failure |
|
| 1:20 |
Overview of natural history and clinical course |
| 1:50 |
Everything we know (or don't know) about LV outflow obstruction |
| 2:25 |
The left atrium, atrial fibrillation and radiofrequency ablation |
| 3:00 |
Break |
| 3:25 |
The spectrum of heart failure in HCM: Clinical-pathologic correlations |
| 4:00 |
Clinical evidence for myocardial ischemia, coronary flow reserve, and mechanisms of heart failure |
| 4:30 |
The "end-stage" and nonobstructive HCM |
| 5:00 |
Role for advanced heart failure management/transplant |
| 5:25 |
Feline HCM: A spontaneous animal model of human disease |
| 6:00 |
Adjournment |
Attendee Dinner
On Friday evening, we invite faculty and attendees to gather for dinner at Windows
on Minnesota, located on the 50th floor of the IDS Center.
Network with expert faculty members and your fellow attendees while enjoying views
overlooking some of the 22 lakes within the city limits of Minneapolis, the new
Twins stadium at Target Field, and the “mighty Mississippi” River. Heralded by The
New York Times as “one of the finest skyscrapers built in any American City,” the IDS
Center is the tallest building in Minnesota and the centerpiece of the downtown
Minneapolis skyline.
The IDS Center is centrally located on Nicollet Mall, a thriving commercial district
with shops, shopping malls, restaurants, bars, arts, entertainment and sight-seeing
opportunities.
WINDOWS ON MINNESOTA
50th Floor, IDS Center | 80 South 8th Street | Minneapolis
Please RSVP for dinner on the registration page - there is no charge to attend.
Saturday, September 28, 2013
|
Time |
Topic |
| 7:30 |
Continental breakfast and exhibits |
|
Identification of the High-Risk Patient and Prevention of Sudden Death |
|
|
8:15 |
Risk stratification strategies and identification of the high risk patients |
|
8:50 |
The "benign" (no risk factor) patients who are nevertheless at risk |
|
9:20 |
Contrast CMR with late gadolinium enhancement: The new sudden death risk marker |
|
9:55 |
Break |
|
10:20 |
Mutations and prediction of prognosis - sudden death, or lack thereof? What about double hits? |
|
10:55 |
Saving young lives: Prevention of sudden death in children and adults with the implantable cardioverter-defibrillator (ICD) |
|
11:30 |
Decision-making and alternative devices for sudden death prevention. What about the subcutaneous ("leadless") ICD for HCM? |
|
12:05 |
Electrophysiologic substrate in HCM: Why appropriate shocks are really appropriate, and their triggers |
|
12:35 |
Luncheon address: The HCMA: Role of patient advocacy groups; update on the evolution of HCM centers of excellence in the U.S. |
|
HCM Around the World |
|
|
1:50 |
HCM and industry: It's the leads…stupid |
|
2:20 |
Italy: Ischemia and scars in the era of contrast-CMR |
|
2:50 |
What's going on in Rotterdam with the myectomy operation and alcohol ablation? |
|
3:20 |
Iceland: Tracing HCM to its origins |
|
3:50 |
Break |
|
4:15 |
Italy Again: Athlete's heart and its distinction from HCM: Comparing U.S. and ESC athlete consensus guidelines for eligibility/disqualification from sports competition to reduce risk |
|
4:40 |
Fabry. What is it exactly…and what should cardiologists know? |
|
5:15 |
In memorium of Gary Tinsley, University of Minnesota Point: The Italian model saves lives and the U.S. needs it Counterpoint: The Italian model doesn't work, and you don't need it |
|
6:00 |
Adjournment |
Sunday, September 29, 2013
|
Time |
Topic |
|
7:30 |
Continental breakfast |
|
Strategies for Treatment of Heart Failure |
|
|
8:15 |
Pharmacologic treatment strategies and timing for myectomy |
|
8:50 |
Techniques and results of surgical septal myectomy: The historic gold standard |
|
9:25 |
Morphologic heterogeneity of the mitral apparatus & relation to septal reduction therapy |
|
9:55 |
Surgical myectomy in Canada |
|
10:30 |
The return of myectomy to Europe? |
|
11:00 |
Debate: Surgical myectomy vs. alcohol ablation Point: Myectomy is preferred and the “gold standard” Counterpoint: Wait a minute – alcohol ablation is better |
|
12:00 |
Closing: HCM is now a contemporary treatable disease |
|
12:05 |
Adjournment |
REGISTRATION & LOGISTICS
Tuition
$695 for physicians
$295 for other health professionals, residents and fellows
$195 for patients
Tuition includes summit materials, breakfast, lunch and refreshments. Advanced registrations are required and will be accepted until Thursday, September 12, 2013. To ensure a comfortable environment, attendance may be capped; early registration is recommended.
Discounted Hotel Reservations
Rooms have been reserved at the Hyatt Regency Minneapolis at a discounted rate of $184 for a single or double, $209 for a triple, and $234 for a quad (plus tax). To ensure the discounted rate, reservations should be made before Wednesday, September 5, 2013.
Click here to make a room reservation online.
To make a room reservation by phone: 1-888-421-1442 (U.S. callers) or 1-402-593-8615 (international callers). To get the group rate, mention Minneapolis Heart Institute Foundation and the event dates.
Cancellation and Refund Policy
Substitutions are accepted at any time. For cancellations received a minimum of one week before the event date, a $50 processing fee will be retained and the tuition balance refunded. Notices after this date will not receive a refund. To complete your cancellation or substitution call 612-863-7806 or email HCMsummit@mhif.org
In the event that this summit would have to be cancelled, Minneapolis Heart Institute Foundation is not responsible for any airfare, hotel or other costs incurred by participants. In the event of an emergency, we reserve the right to cancel a session or substitute a qualified speaker.
Questions
For questions about the summit please call 612-863-7806 or email HCMsummit@mhif.org
Special needs
The sponsors of this activity are fully committed to accommodating the special needs of participants. We will do everything possible to fulfill any requests submitted in writing no later than Thursday, September 12, 2013. Accommodations or special needs requested after that time frame cannot be guaranteed. You may email HCMSummit@mhif.org or fax 612-863-3801 with any special requests.
FACULTY
Michael J. Ackerman, MD, PhD
Mayo Clinic
Rochester, Minnesota
Berglind Adalsteinsdottir, MD
Landspitali University Hospital
Akureyri, Iceland
Cristina Basso, MD, PhD
Institute of Anatomic Pathology
University of Padua
Padua, Italy
Eugene Braunwald, MD
Brigham and Women’s Hospital,
Boston, Massachusetts
Franco Cecchi, MD
University of Florence
Florence, Italy
Domenico Corrado, MD, PhD
University of Padua Medical School
Padua, Italy
Joseph A. Dearani, MD
Mayo Clinic
Rochester, Minnesota
Robert J. Desnick, PhD, MD
Dean for Genetic and Genomic Medicine; Professor and Chair Emeritus, Dept of Genetics and Genomic Sciences
Mount Sinai School of Medicine
New York, NY
N.A. Mark Estes, III, MD
Tufts Medical Center
Boston, Massachusetts
David Feldman, MD, PhD, FACC, FAHA
Medical Director, Heart Failure, VAD and Transplant Programs, Minneapolis Heart Institute® at Abbott Northwestern Hospital; Adjunct Associate Professor, Georgia Institute of Technology & Morehouse School of Medicine
Philip R. Fox, DVM, MS, DACVIM/ECVIM, DACVECC
Caspary Research Institute, Animal Medical Center
New York, NY
Gunnar Thor Gunnarsson
Akureyri Hospital
Akureyri, Iceland
Robert G. Hauser, MD, FACC
Minneapolis Heart Institute® at Abbott Northwestern Hospital
Minneapolis, Minnesota
Carolyn Y. Ho, MD
Brigham and Women's Hospital
Boston, Massachusetts
Harry M. Lever, MD
Cleveland Clinic Foundation
Cleveland, Ohio
Mark S. Link, MD
Tufts Medical Center,
Boston, Massachusetts
Barry J. Maron, MD
Minneapolis Heart Institute Foundation
Minneapolis, Minnesota
Martin S. Maron, MD
Tufts Medical Center
Boston, Massachusetts
Iacopo Olivotto, MD
Careggi University Hospital
Florence, Italy
Steve R. Ommen, MD
Mayo Clinic
Rochester, Minnesota
Antonio Pelliccia, MD
Institute of Sports Medicine
Italian National Olympic Committee
Rome, Italy
Lisa Salberg
Hypertrophic Cardiomyopathy Association (HCMA)
Hibernia, New Jersey
Christine E. Seidman, MD
Department of Genetics
Brigham and Women’s Hospital
Boston, Massachusetts
Christopher Semsarian, MD PhD
Centenary Institute
University of Sydney
New South Wales, Australia
Mark V. Sherrid, MD
St. Luke's-Roosevelt Hospital Center;
Columbia University College of Physicians and Surgeons
New York City, New York
Ulrich Sigwart, MD, FACC FESC, FRCP
University of Geneva
Geneva, Switzerland
Paolo Spirito, MD
Ente Ospedaliero Ospedali Galleria
Genoa, Italy
Folkert J. ten Cate, MD, PhD
Erasmus Medical Center
Rotterdam, The Netherlands
Gaetano Thiene, MD
Institute of Anatomic Pathology
University of Padua
Padua, Italy
Jeffrey A. Towbin, MD, FAAP, FACC, FAHA
Cincinnati Children’s Hospital,
Cincinnati, Ohio
Sami Viskin, MD
The Tel-Aviv Sourasky Medical Center
Tel Aviv, Israel
Anna Woo, MD, FRCPC, FACC
Toronto General Hospital
Toronto, Ontario
When & Where
Hyatt Regency Minneapolis
1300 Nicollet Mall
Minneapolis,
MN 55403
Friday, September 27, 2013 at 7:30 AM - Sunday, September 29, 2013 at 12:05 PM (CDT)
Add to my calendar
Organizer
Minneapolis Heart Institute Foundation & Allina Health
The Minneapolis Heart Institute Foundation (MHIF) is working to create a world without heart disease. Through groundbreaking clinical research, professional education and health behavior change programs, we are improving individuals’ quality of life and reducing the mortality rate associated with cardiovascular disease.
As the research, education and philanthropic arm of the Minneapolis Heart Institute, MHIF is an independent, not-for-profit, community-based foundation. Among the top ten clinical cardiovascular research and education institutions in the country, we conduct more than 100 clinical research studies in the course of a year. Locally, we have reduced the 30-day heart attack mortality rate by more than 50% for individuals within a 210 mile radius of Minneapolis. Building upon this protocol, our therapeutic hypothermia trial is further advancing emergency cardiac care services and has improved survival rate by 28%.
Allina Health is a not-for-profit integrated delivery system of hospitals, clinics and other health care services. Nearly 24,000 employees, 5,000 physicians and 2,500 volunteers are dedicated to meeting the lifelong health care needs of communities throughout Minnesota and western Wisconsin.
Funding for this project is provided by the Center for Prevention at Blue Cross and Blue Shield of Minnesota, as part of the Blue Cross’ long-term commitment to tackle the four leading causes of heart disease and cancer: tobacco use, obesity, lack of physical activity and unhealthy eating.